EQRx — Merger or Acquisition (August 2023)
39 slides from EQRx's merger presentation, Aug 1, 2023
Slide 1: On Target to Outsmart Cancer
Aug 1, 2023 On Target to Outsmart Cancer TM © 2023 Revolution Medicines
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding the expected timing of closing of the pro
Slide 3: Summary of Transaction and Business Updates
Summary of Transaction and Business Updates Announced August 1, 2023 • RVMD to acquire EQRx in an all-stock transaction to gain more than $1B in additional capital • Strengthened balance sheet intended to support RVMD’s parallel, late-stage development for RAS(ON) Inhibitor pipeline, which includes
Slide 4: On Target to Outsmart Cancer
On Target to Outsmart Cancer HIGH UNMET NEED IN RAS-ADDICTED CANCERS 30% of human cancers(1), largely unserved by targeted therapeutics STRONG CLINICAL VALIDATION OF RASMUTANT AS CANCER DRIVER Proof-of-principle from first-gen KRASG12C inhibitors(2) DEEP, SCIENCE-DRIVEN CLINICAL AND PRECLINICAL PIPE
Slide 5: Excessive RAS(ON) Signaling Drives 30% of Human Cancers
Excessive RAS(ON) Signaling Drives 30% of Human Cancers, Targeted by Our Pipeline Strategy RAS-Addicted Cancers = RAS(OFF) Normal RAS Cancer Mutations New patients per year (U.S.)(1) = RAS(ON) 230,000 All Cell Membrane 67,000 Lung cancer Tightly regulated Excessive control RAS(ON) cell proteins grow
Slide 6: Deep, Science-Driven Clinical and Preclinical Pipeline for RAS-Addicted Cancers
Deep, Science-Driven Clinical and Preclinical Pipeline of Targeted Therapies for RAS-Addicted Cancers RAS(ON) Inhibitors RAS Companion Inhibitors 3 Clinical-stage 2 Drug Clinical-stage Candidates Drug Candidates RAS COOPERATING Development-stage TARGETS 2 Drug Candidates RAS(ON) 1 IND-ready Drug Can
Slide 7: Groundbreaking RAS(ON) Inhibitors Bind Near RAS Cancer Mutation Hotspots
Groundbreaking RAS(ON) Inhibitors Bind Near RAS Cancer Mutation Hotspots and Suppress Cancer Signaling Bind Suppress r Cyclophilin A RAS-Q61 RAS-G12 RAS-G13 Inhibited RAS(ON) Oncogenic RAS(ON) Oncogenic RAS(ON) • Potent, selective, oral and drug-like inhibitors • Deep and sustained suppression of RA
Slide 8: Current Portfolio of RAS(ON) Inhibitors Targets Every RAS Mutation Hotspot
Current Portfolio of RAS(ON) Inhibitors Targets Every RAS Cancer Mutation Hotspot(1) Relative Frequency in Human RAS Cancers(2) RMC-6236 MULTI/G12X Q61 RMC-0708 Q61H RMC-6291 G12C G12 RMC-9805 G12D G13 RMC-8839 G13C (1) RAS cancer mutation hotspots defined as G12, G13 and Q61 8 (2) Calculated using
Slide 9: RMC-6236: First-in-Class RASMULTI(ON) Inhibitor
RMC-6236: First-in-Class RASMULTI(ON) Inhibitor with Broad Potential Against RAS-Addicted Cancers Preclinical Profile Colorectal Highly Potent and Selective RAS(ON) Inhibitor 32% • Suppresses diverse mutant RAS cancer drivers Pancreatic and cooperating wild-type RAS proteins 32% 137,000 Robust Anti-
Slide 10: RMC-6236: Highly Active with Durable Benefit Across in Vivo Models
RMC-6236: Highly Active with Durable Benefit Across in Vivo Models of Major Human Cancers with KRASG12X Drivers NSCLC PDAC CRC PFS 53% ORR (8/15) 61% ORR (11/18) 44% ORR (8/18) RMC-6236 – Median not reached 100% DCR (15/15) 89% DCR (16/18) 56% DCR (10/18) Control – Median 9 days 100 Free—75 mPD Tumo
Slide 11: RMC-6236 Phase 1/1b Trial: Clinical Translation of Preclinical Profile
RMC-6236 Phase 1/1b Trial: Clinical Translation of Preclinical Single Agent Profile and Initial Platform Validation Preclinical Profile Aims of Phase 1/1b Clinical Trial(2) ü Oral dosing (daily and intermittent): drug and levels that drive sustained RAS pathway o Oral dosing: complete dose optimizat
Slide 12: RMC-6236-001: Treatment-Related AEs Occurring in ≥10% of Patients
RMC-6236-001: Treatment-Related AEs Occurring in ≥ 10% of All Patients 10 mg QD 20 mg QD 40 mg QD 80 mg QD 120 mg QD Overall (N=3) (N=13) (N=9) (N=7) (N=4) (N=36) Preferred Any Grade Any Grade Any Grade Any Grade Any Grade Any Grade Term Grade ≥3 Grade ≥3 Grade ≥3 Grade ≥3 Grade ≥3 Grade ≥3 Rash (CM
Slide 13: RMC-6236-001: Change in Tumor Burden in KRASG12X NSCLC or Pancreatic Cancer
RMC-6236-001: Change in Tumor Burden from Patients with KRASG12X NSCLC or Pancreatic Cancer Treated at ≥ 40 mg Daily 120 mg QD 80 mg QD 40 mg QD = on treatment PDAC PDAC NSCLC PDAC PDAC PDAC NSCLC PDAC PDAC PDAC NSCLC PDAC G12V G12D G12A G12D G12D G12D G12D G12D G12V G12V G12D G12D Most recent scan:
Slide 14: RMC-6236-001 Case Report: KRASG12D Pancreatic Cancer Patient
RMC-6236-001 Case Report: KRASG12D Pancreatic Cancer Patient • 76 year-old male • KRASG12D pancreatic cancer diagnosed November 2017 • Treated with neoadjuvant chemotherapy, surgery, adjuvant chemotherapy 2018 • Progressed with metastatic disease January 2022; treated with gemcitabine + nab-paclitax
Slide 15: Updated Case Report: Confirmed PR for KRASG12D Pancreatic Cancer Patient
Updated RMC-6236-001 Case Report: Confirmed PR for KRASG12D Pancreatic Cancer Patient Target Lesion 1 (Lung RLL) Target Lesion 2 (Lung LLL) Non-Target Lesion (Lung LLL) SLD: Baseline 45.6 mm C7D1 6236, SLD: 8.0 mm Treatment -On RMC 15 RLL=right lower lobe; LLL=left lower lobe Images courtesy of RMC-
Slide 16: Planning is Underway for Next Steps with RMC-6236 Clinical Development
Planning is Underway for Next Steps with RMC-6236 Clinical Development o Current RMC-6236-001 trial: dose optimization for pivotal trials is Agent ongoing o One or more pivotal trials: late-stage evaluation of treatment with Single RMC-6236 in patients with KRASG12X–bearing tumors potentially to beg
Slide 17: RMC-6291: Mutant-Selective RAS(ON) Inhibitor for KRASG12C Cancers
RMC-6291: Mutant-Selective RAS(ON) Inhibitor with Best-in-Class Potential for KRASG12C Cancers Preclinical Profile Highly Potent and Selective RAS(ON) Inhibitor Lung 76% • Highly active against KRASG12C • Covalent for irreversible inhibition • Low off-target risk and acceptable safety profile 29,000
Slide 18: RMC-6291: Superior Response Rates and Durability in Mouse Clinical Trial
RMC-6291: Superior Response Rates and Durability in Mouse Clinical Trial with 25 KRASG12C NSCLC Models Responses PFS RMC-6291 – Median not reached Adagrasib – Median not reached 72% (18/25) ORR 52% (13/25) ORR 100 Control – Median 9 days 92% (23/25) DCR 72% (18/25) DCR mPD Free 75 -Tumors 50 mSD % P
Slide 19: RMC-6291 Phase 1/1b Trial: Clinical Translation of Preclinical Profile
RMC-6291 Phase 1/1b Trial: Clinical Translation of Preclinical Single Agent Profile and Initial Platform Validation Preclinical Profile Aims of Phase 1/1b Clinical Trial(2) ü Oral dosing (daily): drug levels that drive o Oral dosing: once daily or BID to reach active and maximal target crosslinking
Slide 20: RMC-9805: First-in-Class Mutant-Selective RAS(ON) Inhibitor for KRASG12D Cancers
RMC-9805: First-in-Class Mutant-Selective RAS(ON) Inhibitor for KRASG12D Cancers Preclinical Profile Highly Potent and Selective RAS(ON) Inhibitor Pancreatic 38% 40% Colorectal • Highly active against KRASG12D • Covalent for irreversible inhibition • Low off-target risk and acceptable safety profile
Slide 21: RMC-9805: Selective, Covalent Binding and Inhibition of KRASG12D(ON)
RMC-9805: Selective, Covalent Binding and Inhibition of KRASG12D(ON) with Apoptosis Induction in Vivo Selective Covalent Binding to KRASG12D(ON) RAS Signaling Inhibition and Apoptosis Induction(2) KRAS: WT G12D G13D G12C G13C X-linked KRAS KRAS Control RMC-9805 H/NRAS Drug Exposure and Pathway RAS s
Slide 22: RMC-9805: Highly Active in Vivo Across Diverse KRASG12D Cancer Models
RMC-9805: Highly Active in Vivo Across Diverse KRASG12D Cancer Models NSCLC PDAC CRC 67% ORR (6/9) 78% DCR (7/9) RVMD preclinical research as of 11/02/22 RMC-9805 dosed at 100 mg/kg po qd; n=2-8/group 22 NSCLC Responses = non-small assigned cell according lung cancer; to mRECIST PDAC = (see pancreat
Slide 23: RMC-9805 Phase 1/1b Trial: Clinical Translation of Preclinical Profile
RMC-9805 Phase 1/1b Trial: Clinical Translation of Preclinical Single Agent Profile Preclinical Profile Aims of Phase 1/1b Clinical Trial(2) ü Oral dosing (daily): drug levels that drive to reach active and maximal target crosslinking and sustained o Oral dosing: once daily or BID exposures; surroga
Slide 24: RAS(ON) Inhibitors Drive Tumor Regressions in Models of Brain Metastasis
RAS(ON) Inhibitors Drive Tumor Regressions in Models of Brain Metastasis LU99(1) LU99 HPAC high (NSCLC, KRASG12C) (PDAC, KRASG12D) Control Brain Xenograft(1) Brain Xenograft(2) 1011 Adagrasib 1010 low 109 108 RMC-6236 (photons/sec) 107 Bioluminescence 106 RMC-6291 105 l b 6 1 l 5 (2) r o i 3 9 r o 0
Slide 25: RAS(ON) Inhibitors Induce Anti-Tumor Immunity in Immunocompetent Models
RAS(ON) Inhibitors Induce Anti-Tumor Immunity via Multiple Mechanisms in Immunocompetent Models Control Control Control Anti-PD1 Anti-PD1 Anti-PD1 RMC-6236 RMC-6291 RMC-9805 Combination Combination Combination G12C G12C G12D free 100 Mechanisms of Action—75 -Antigen presentation 50 ¯ Myeloid suppres
Slide 26: RMC-0708: First-in-Class Mutant-Selective RAS(ON) Inhibitor for KRASQ61H Cancers
RMC-0708: First-in-Class Mutant-Selective RAS(ON) Inhibitor for KRASQ61H Cancers Preclinical Profile Pancreatic Colorectal 23% Highly Potent and Selective RAS(ON) Inhibitor 22% • Highly active against KRASQ61H • Non-covalent, highly selective over wild-type RAS • Low off-target risk and acceptable s
Slide 27: RMC-0708: Sustained Pathway Inhibition and Tumor Regressions in KRASQ61H Models
RMC-0708: Sustained Pathway Inhibition in Vivo and Tumor Regressions in KRASQ61H Cancer Models NSCLC(2) PDAC(3) Drug Exposure and Pathway 3 ) 2000 2000 Control Suppression after Oral Dosing(1,2) (mm e RMC-0708 1500 1500 Tumor PD Blood PK Tumor PK Volum 100 1000 1000 10000 Dosing Dosing Start Start m
Slide 28: On Target to Outsmart Pancreatic Cancer
On Target to Outsmart Pancreatic Cancer: RAS(ON) Inhibitors Designed to Cover All KRASMUTANT Drivers(1) Devastating disease >90% driven by KRAS mutations G12D RMC-6236 & RMC-9805 49,000 New KRASMUTANT pancreatic cancer G12V RMC-6236 patients per year (U.S.)(1). No approved targeted therapies G12R RM
Slide 29: RAS Companion Inhibitors
RMC-6236 RAS Companion Inhibitors WT RAS RMC-5552 Cooperating Designed to Suppress Targets and Pathways that mTORC1 Sustain RAS-Addicted RAS(ON) Cancers RMC-4630 CANCER DRIVERS SHP2
Slide 30: Evaluation of RMC-4630 in Combination with Sotorasib in KRASG12C Patients
3 0 Evaluation of RMC-4630 in Combination with Sotorasib in KRASG12C Cancer Patients Phase 1/1b Clinical Trial(1) Aims of RMC-4630-03 Phase 2 Trial(4) ü Selected single agent RP2DS: Oral dosing of o Dosing: Focused primarily on 200 mg D1D2 200 mg D1D2 weekly: well-tolerated, safety and weekly combin
Slide 31: RMC-5552: First-in-Class Bi-steric mTORC1-Selective Inhibitor
RMC-5552: First-in-Class Bi-steric mTORC1-Selective Inhibitor for Cancers with Hyperactive mTOR Signaling Rapalogs mTOR Highly Potent and Selective mTORC1 Inhibitor active site RMC-5552 inhibitors • Bi-steric mechanism enables selectivity for mTORC1 • Capable of reactivating the tumor suppressor 4EB
Slide 32: RMC-5552: Profile as a Potential Single Agent RAS Companion Inhibitor
RMC-5552: Compelling Profile as a Potential Phase 1/1b Single Agent Study RAS Companion Inhibitor Best Tumor Change in Efficacy Evaluable Patients Treated at 6 mg or 8 mg IV Weekly Preliminary radiologic and molecular 71% DCR(2) evidence of activity at tolerated doses: • Disease control across diver
Slide 33: RMC-5552 Phase 1/1b Trial: Clinical Optimization of Single Agent Profile
RMC-5552 Phase 1/1b Trial: Clinical Optimization of Single Agent Profile for Combination with RAS(ON) Inhibitor Portfolio Preclinical Profile Aims of Phase I/Ib Clinical Trial(1) and ü Dosing: Once weekly dosing achieves levels o Dosing: Establish optimal IV regimen based on that drive sustained inh
Slide 34: Overcoming Resistance: RMC-6291 + RMC-6236 Combination Induces Regressions
Overcoming Resistance: RMC-6291 + RMC-6236 Combination Induces Regressions in KRASG12C NSCLC Model 1000 Control ) 3 800 RMC-6291 (mm RMC-6236 600 Combination Volumestart Tumor 400 Dosing Mean 200 0 5 15 25 35 Days post-implant RASMULTI(ON) Inhibitor Deployed as a RAS Companion Inhibitor RVMD preclin
Slide 35: Deep Pipeline of Targeted Therapies for Majority of RAS-Addicted Cancers
Deep Pipeline of Targeted Therapies for Majority of RAS-Addicted Cancers PRECLINICAL IND-ENABLING CLINICAL PHASE 1 CLINICAL PHASE 2 CLINICAL PHASE 3 RAS(ON) INHIBITORS RMC-6236 RASMULTI RMC-6291 KRASG12C RMC-9805 KRASG12D RMC-0708 KRASQ61H RMC-8839 KRASG13C Pipeline G12R, G12V, G13D, Expansion Q61X,
Slide 36: Anticipated Milestones
Anticipated Milestones MILESTONE (EXPECTED TIMING) RAS(ON) INHIBITORS RMC-6236 (RASMULTI) Report further evidence of first-in-class single agent activity (Oct 2023) Report preliminary evidence of differentiation from KRASG12C(OFF) inhibitors RMC-6291 (KRASG12C) (Oct 2023) RMC-9805 (KRASG12D) Announc
Slide 37: Financial Information
Financial Information Financial Position Cash, cash equivalents and marketable securities as of $909.8 million(1) March 31, 2023 2023 Financial Guidance 2023 GAAP net loss of $360 million to $400 million(2) (1) With current cash, cash equivalents and marketable securities, the company projects it ca
Slide 38: On Target to Outsmart Cancer
TM On Target to Outsmart Cancer Focused on serving high unmet needs across numerous cancers driven by diverse RAS mutations First two targeted RAS(ON) Inhibitors have shown initial clinical activity and evaluation continues Targeted RAS Companion Inhibitors designed to counter drug resistance have s
Slide 39: Appendix
Appendix • RAS cancer epidemiology statistics are estimated using tumor mutation frequencies from Foundation Medicine Insights August 2020 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2020: • RAS mutations include: KRAS G12(A,C,D,R,S,V), KRAS G13(C